Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
– Atebimetinib in combination with chemotherapies has shown excellent results in Phase 2, including long survival and an outstanding tolerability profile in an all-comers population of first-line pancreatic cancer patients treated with

Follow